Delving into the Latest Updates on Zhengzhou Taifeng Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

NCC(Thiazide-sensitive sodium-chloride cotransporter)	1

主要目的：以郑州泰丰制药有限公司研制的恩格列净片为受试制剂，以Boehringer Ingelheim International GmbH持证的恩格列净片（商品名：Jardiance®）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。次要目的：评价中国健康受试者单次空腹/餐后口服恩格列净片受试制剂和参比制剂后的安全性。

[Translation]

Main purpose: Using empagliflozin tablets developed by Zhengzhou Taifeng Pharmaceutical Co., Ltd. as the test preparation and empagliflozin tablets (trade name: Jardiance®) certified by Boehringer Ingelheim International GmbH as the reference preparation, the pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial state were investigated to evaluate whether the two preparations are bioequivalent. Secondary purpose: To evaluate the safety of the test preparation and reference preparation of empagliflozin tablets after a single oral administration in fasting/postprandial state in healthy Chinese subjects.

Start Date31 May 2024

Sponsor / Collaborator

Zhengzhou Taifeng Pharmaceutical Co., Ltd.

CTR20240950 / CompletedNot Applicable

达格列净片在健康受试者中随机、开放、两制剂、单次给药、两周期、双交叉空腹和餐后状态下的生物等效性试验

[Translation] A randomized, open-label, two-dose, single-dose, two-period, double-crossover bioequivalence study of dapagliflozin tablets in healthy subjects under fasting and fed conditions

主要目的：以郑州泰丰制药有限公司研制的达格列净片为受试制剂，以AstraZeneca AB持证的达格列净片（商品名：Farxiga®）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。次要目的：评价中国健康受试者单次空腹/餐后口服达格列净片受试制剂和参比制剂后的安全性。

[Translation]

Main purpose: Using dapagliflozin tablets developed by Zhengzhou Taifeng Pharmaceutical Co., Ltd. as the test preparation and dapagliflozin tablets (trade name: Farxiga®) licensed by AstraZeneca AB as the reference preparation, the pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial state were investigated to evaluate whether the two preparations are bioequivalent. Secondary purpose: To evaluate the safety of the test preparation and reference preparation of dapagliflozin tablets after a single oral administration in Chinese healthy subjects on an empty stomach or after a meal.

Start Date24 Apr 2024

Sponsor / Collaborator

Zhengzhou Taifeng Pharmaceutical Co., Ltd.

CTR20240614 / CompletedNot Applicable

评估受试制剂匹维溴铵片（规格：50 mg）与参比制剂Dicetel®（规格：50 mg）在健康成年受试者空腹和餐后状态下的单中心、随机、开放、单剂量（50 mg）四周期、两序列、完全重复交叉生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose (50 mg) four-period, two-sequence, fully repeated crossover bioequivalence study was conducted to evaluate the bioequivalence of the test preparation, Pinaverium Bromide Tablets (strength: 50 mg), and the reference preparation, Dicetel® (strength: 50 mg), in healthy adult subjects in the fasting and fed state.

主要研究目的：研究空腹和餐后状态下单次口服受试制剂匹维溴铵片（规格：50 mg，郑州泰丰制药有限公司生产）与参比制剂匹维溴铵片（Dicetel®，规格：50 mg，Mylan Laboratories SAS生产）在健康受试者体内的药代动力学，评价空腹和餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂匹维溴铵片（规格：50 mg）和参比制剂匹维溴铵片（Dicetel®，规格：50 mg）在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation Pinaverium Bromide Tablets (Specification: 50 mg, produced by Zhengzhou Taifeng Pharmaceutical Co., Ltd.) and the reference preparation Pinaverium Bromide Tablets (Dicetel®, Specification: 50 mg, produced by Mylan Laboratories SAS) in healthy subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study: to evaluate the safety of the test preparation Pinaverium Bromide Tablets (Specification: 50 mg) and the reference preparation Pinaverium Bromide Tablets (Dicetel®, Specification: 50 mg) in healthy subjects.

Start Date22 Mar 2024

Sponsor / Collaborator

Zhengzhou Taifeng Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhengzhou Taifeng Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhengzhou Taifeng Pharmaceutical Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Zhengzhou Taifeng Pharmaceutical Co., Ltd.

01 Jul 2024·Drug Delivery and Translational Research

pH and redox dual response nano-suppository for the treatment of ulcerative colitis

Article

Author: Song, Jinfeng ; Li, Longxia ; Wu, Yijun ; Wang, Xiaochen ; Chang, Jie ; Ma, Yunfeng

To improve treatment compliance and reach sustained and controlled drug release in the colon, we developed a hollow mesoporous silica nano-suppository that responded to both pH and redox stimuli. Firstly, we prepared hollow mesoporous silica nanoparticles containing disulfide bonds (HMSN-SS) and loaded them with 5-ASA. Secondly, we modified the surface of HMSN-SS with polydopamine (PDA) and chitosan (CS) and molded the suppository, which we named 5-ASA@HMSN-SS-PDA-CS (5-ASA@HSPC). By administering 5-ASA@HSPC rectally, it acted directly on the affected area. CS helped the nanoparticles adhere to the colon's surface, while PDA dissociates from HMSN-SS due to protonation in the acidic environment of the ulcerative colon. The disulfide bonds were destroyed by the reducing environment of the colon, leading to a stable and slow release of encapsulated 5-ASA from the pores of HMSN. Finally, in vitro release experiments and in vivo pharmacokinetic and pharmacodynamic experiments had demonstrated that 5-ASA@HSPC exhibited a slow and steady action at the colonic site, with an excellent safety profile. This novel approach showed great potential in the treatment of ulcerative colitis.

100 Deals associated with Zhengzhou Taifeng Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhengzhou Taifeng Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data